Skip to main content
OpenTrials
Completed

NCT Number: NCT01196832

Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.

Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Bordeaux

Pessac, 33604, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
  • Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
  • Written informed consent

Exclusion criteria

  • Subject without any social security or health insurance
  • Asthma, lung fibrosis or idiopathic pulmonary hypertension
  • Chronic viral infections (hepatitis, HIV)

Treatment and study plan

Blood sample

Procedure

blood sample for fibrocytes analysis

Clinical and functional evaluation

Procedure

Plethysmography, Carbon monoxide capacity of transfer , arterial gaz

Primary outcomes

  1. Number of circulating blood fibrocytes

    Time frame: Day 1

    Sampling of blood in Chronic obstructive pulmonary disease patients

  2. Number of circulating blood fibrocytes

    Time frame: 2 months

    Sampling of blood in Chronic obstructive pulmonary disease patients

Secondary outcomes

  1. Characterization of fibrocytes

    Time frame: Day 1 and at 2 months

    Sampling of blood

  2. Differenciation of blood fibrocytes

    Time frame: Day 1 and at 2 months

    Sampling of blood

  3. Chemotactism of blood fibrocytes

    Time frame: Day 1 and at 2 months

    Sampling of blood

  4. Number of exacerbation

    Time frame: 12 months after V2

  5. Mortality

    Time frame: 12 months after V2

  6. Annual decline of ventilatory function

    Time frame: 12 months after V2

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

Role of Fibrocytes in the Bronchial Remodeling of Chronic Obstructive Pulmonary Disease

Acronym: FIREBROB

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Sep 9, 2010
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.